Search results
Duchenne Muscular Dystrophy (DMD) Treatment
Verywell Health via Yahoo News· 1 month agoInsights Into Treatment Advancements Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD Duchenne muscular dystrophy...
Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
Zacks via Yahoo Finance· 2 months agoSarepta Therapeutics, Inc. SRPT reported adjusted earnings of 73 cents per share in the first...
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and...
Zacks via Yahoo Finance· 7 months agoFor Immediate Release Chicago, IL – November 21, 2023 – Zacks.com announces the list of stocks...
US FDA approves Italfarmaco's drug for Duchenne muscle-wasting disorder
Reuters via Yahoo News· 3 months agoThe U.S. FDA has approved privately held Italfarmaco Group's drug to treat Duchenne muscular...
Got $3,000? 3 Growth Stocks to Double Up On Right Now
Motley Fool via Yahoo Finance· 5 months agoAre you looking for some new growth stocks to add to your portfolio? There's certainly no shortage...
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta...
Zacks via Yahoo Finance· 5 months agoFor Immediate Release Chicago, IL – January 11, 2024 – Zacks.com announces the list of stocks...
A Comprehensive Look at Sarepta's Growth and Innovation
GuruFocus.com via Yahoo Finance· 3 months agoSarepta Therapeutics, Inc. (NASDAQ:SRPT) is an American pharmaceutical company leading the global...
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
Zacks via Yahoo Finance· 4 months agoFor Immediate Release Chicago, IL – February 14, 2024 – Today, Zacks Equity Research discusses...
Reata shares triple after surprise FDA nod for rare disease drug
Reuters via Yahoo News· 1 year agoReata's drug Skyclarys is the first approved treatment for Friedreich's Ataxia, a rare genetic disorder that causes progressive damage to the nervous system and can lead to premature death.
UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
TipRanks via Yahoo Finance· 1 year agoRisk and reward should be on every investor’s mind right now, and for good reason. The risks of...